Connection

Sakamuri Reddy to Bone Resorption

This is a "connection" page, showing publications Sakamuri Reddy has written about Bone Resorption.
Connection Strength

2.742
  1. Inhibition of NFAM1 suppresses phospho-SAPK/JNK signaling during osteoclast differentiation and bone resorption. J Cell Biochem. 2021 10; 122(10):1534-1543.
    View in: PubMed
    Score: 0.745
  2. Proteasome inhibition suppress microgravity elevated RANK signaling during osteoclast differentiation. Cytokine. 2020 01; 125:154821.
    View in: PubMed
    Score: 0.655
  3. Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter. Gene. 2006 Apr 12; 371(1):16-24.
    View in: PubMed
    Score: 0.254
  4. Sphingosine-1-Phosphate Receptor 2 Controls Podosome Components Induced by RANKL Affecting Osteoclastogenesis and Bone Resorption. Cells. 2019 01 01; 8(1).
    View in: PubMed
    Score: 0.157
  5. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells. J Cell Physiol. 2018 08; 233(8):6125-6134.
    View in: PubMed
    Score: 0.148
  6. NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone. Bone. 2017 Aug; 101:236-244.
    View in: PubMed
    Score: 0.140
  7. Microgravity control of autophagy modulates osteoclastogenesis. Bone. 2014 Apr; 61:125-31.
    View in: PubMed
    Score: 0.111
  8. Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone. Endocrinology. 2011 Nov; 152(11):4180-9.
    View in: PubMed
    Score: 0.094
  9. Microarray profile of gene expression during osteoclast differentiation in modelled microgravity. J Cell Biochem. 2010 Dec 01; 111(5):1179-87.
    View in: PubMed
    Score: 0.089
  10. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity. J Cell Biochem. 2008 Jul 01; 104(4):1500-8.
    View in: PubMed
    Score: 0.076
  11. Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. J Immunol. 2006 Aug 15; 177(4):2384-90.
    View in: PubMed
    Score: 0.066
  12. Etiologic factors in Paget's disease of bone. Cell Mol Life Sci. 2006 Feb; 63(4):391-8.
    View in: PubMed
    Score: 0.064
  13. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology. 2005 Apr; 146(4):2023-30.
    View in: PubMed
    Score: 0.059
  14. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr. 2004; 14(4):255-70.
    View in: PubMed
    Score: 0.055
  15. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells. J Steroid Biochem Mol Biol. 2004 May; 89-90(1-5):331-4.
    View in: PubMed
    Score: 0.014
  16. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease. J Bone Miner Res. 2004 Jul; 19(7):1154-64.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.